LEXICON PHARMACEUTICALS INC (LXRX) Fundamental Analysis & Valuation

NASDAQ:LXRX • US5288723027

Current stock price

1.72 USD
-0.04 (-2.27%)
At close:
1.7187 USD
0 (-0.08%)
After Hours:

This LXRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. LXRX Profitability Analysis

1.1 Basic Checks

  • In the past year LXRX has reported negative net income.
  • In the past year LXRX has reported a negative cash flow from operations.
  • In the past 5 years LXRX always reported negative net income.
  • In the past 5 years LXRX always reported negative operating cash flow.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • LXRX has a Return On Assets (-27.21%) which is in line with its industry peers.
  • LXRX has a Return On Equity (-46.81%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -27.21%
ROE -46.81%
ROIC N/A
ROA(3y)-57.19%
ROA(5y)-57.63%
ROE(3y)-124.78%
ROE(5y)-107.73%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400

1.3 Margins

  • LXRX's Gross Margin of 99.45% is amongst the best of the industry. LXRX outperforms 97.40% of its industry peers.
  • LXRX's Gross Margin has improved in the last couple of years.
  • LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.18%
GM growth 5Y1.55%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. LXRX Health Analysis

2.1 Basic Checks

  • LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LXRX has more shares outstanding
  • The number of shares outstanding for LXRX has been increased compared to 5 years ago.
  • LXRX has a better debt/assets ratio than last year.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • LXRX has an Altman-Z score of -9.57. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.57, LXRX is doing worse than 71.88% of the companies in the same industry.
  • LXRX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • LXRX's Debt to Equity ratio of 0.46 is on the low side compared to the rest of the industry. LXRX is outperformed by 61.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -9.57
ROIC/WACCN/A
WACC9.46%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 4.88 indicates that LXRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.88, LXRX is in the better half of the industry, outperforming 66.15% of the companies in the same industry.
  • LXRX has a Quick Ratio of 4.87. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 4.87, LXRX is doing good in the industry, outperforming 67.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.87
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LXRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 78.13% over the past year.
  • LXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.24%.
  • Measured over the past years, LXRX shows a quite strong growth in Revenue. The Revenue has been growing by 15.72% on average per year.
EPS 1Y (TTM)78.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)60.24%
Revenue growth 3Y692.66%
Revenue growth 5Y15.72%
Sales Q2Q%-79.31%

3.2 Future

  • Based on estimates for the next years, LXRX will show a very strong growth in Earnings Per Share. The EPS will grow by 28.16% on average per year.
  • Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 32.17% on average per year.
EPS Next Y-79.67%
EPS Next 2Y-28.25%
EPS Next 3Y0.13%
EPS Next 5Y28.16%
Revenue Next Year-28.92%
Revenue Next 2Y-35.86%
Revenue Next 3Y12.94%
Revenue Next 5Y32.17%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. LXRX Valuation Analysis

4.1 Price/Earnings Ratio

  • LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.25%
EPS Next 3Y0.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LXRX Dividend Analysis

5.1 Amount

  • No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LXRX Fundamentals: All Metrics, Ratios and Statistics

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (4/10/2026, 8:00:01 PM)

After market: 1.7187 0 (-0.08%)

1.72

-0.04 (-2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-12
Earnings (Next)04-30
Inst Owners68.49%
Inst Owner Change0%
Ins Owners1.03%
Ins Owner Change1.14%
Market Cap728.73M
Revenue(TTM)49.80M
Net Income(TTM)-50.34M
Analysts80
Price Target3.43 (99.42%)
Short Float %5.43%
Short Ratio7.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.87%
Min EPS beat(2)40.58%
Max EPS beat(2)43.17%
EPS beat(4)4
Avg EPS beat(4)56.5%
Min EPS beat(4)29.61%
Max EPS beat(4)112.65%
EPS beat(8)7
Avg EPS beat(8)32.73%
EPS beat(12)10
Avg EPS beat(12)21.61%
EPS beat(16)13
Avg EPS beat(16)15.99%
Revenue beat(2)2
Avg Revenue beat(2)135.26%
Min Revenue beat(2)71.44%
Max Revenue beat(2)199.07%
Revenue beat(4)3
Avg Revenue beat(4)184.87%
Min Revenue beat(4)-12.42%
Max Revenue beat(4)481.39%
Revenue beat(8)4
Avg Revenue beat(8)116.99%
Revenue beat(12)5
Avg Revenue beat(12)94.65%
Revenue beat(16)5
Avg Revenue beat(16)45.99%
PT rev (1m)15.07%
PT rev (3m)16.67%
EPS NQ rev (1m)47.08%
EPS NQ rev (3m)47.08%
EPS NY rev (1m)0%
EPS NY rev (3m)5.01%
Revenue NQ rev (1m)66.01%
Revenue NQ rev (3m)66.01%
Revenue NY rev (1m)61.83%
Revenue NY rev (3m)96.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.63
P/FCF N/A
P/OCF N/A
P/B 6.78
P/tB 11.57
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.12
BVpS0.25
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.21%
ROE -46.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.45%
FCFM N/A
ROA(3y)-57.19%
ROA(5y)-57.63%
ROE(3y)-124.78%
ROE(5y)-107.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.18%
GM growth 5Y1.55%
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.87
Altman-Z -9.57
F-Score5
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)92.64%
Cap/Depr(5y)200.58%
Cap/Sales(3y)14.12%
Cap/Sales(5y)348.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y-79.67%
EPS Next 2Y-28.25%
EPS Next 3Y0.13%
EPS Next 5Y28.16%
Revenue 1Y (TTM)60.24%
Revenue growth 3Y692.66%
Revenue growth 5Y15.72%
Sales Q2Q%-79.31%
Revenue Next Year-28.92%
Revenue Next 2Y-35.86%
Revenue Next 3Y12.94%
Revenue Next 5Y32.17%
EBIT growth 1Y75.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.05%
OCF growth 3YN/A
OCF growth 5YN/A

LEXICON PHARMACEUTICALS INC / LXRX Fundamental Analysis FAQ

What is the fundamental rating for LXRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LXRX.


What is the valuation status of LEXICON PHARMACEUTICALS INC (LXRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to LEXICON PHARMACEUTICALS INC (LXRX). This can be considered as Overvalued.


What is the profitability of LXRX stock?

LEXICON PHARMACEUTICALS INC (LXRX) has a profitability rating of 2 / 10.


How financially healthy is LEXICON PHARMACEUTICALS INC?

The financial health rating of LEXICON PHARMACEUTICALS INC (LXRX) is 4 / 10.


What is the earnings growth outlook for LEXICON PHARMACEUTICALS INC?

The Earnings per Share (EPS) of LEXICON PHARMACEUTICALS INC (LXRX) is expected to decline by -79.67% in the next year.